<h4>Background</h4>High PD-L1 expression in non-small cell lung cancer (NSCLC) is evident to predict elevated immunotherapy efficacy, to which NSCLC with onco-driver gene mutations is probed with poor responsiveness. The gene discussed is CD274; the disease is non-small cell lung carcinoma.